索利那新联合坦索罗辛治疗男性下尿路症状伴膀胱过度活动症疗效观察

目的探讨索利那新联合坦索罗辛治疗良性前列腺增生（BPH）伴膀胱过度活动症（OAB）的有效性及安全性。方法采用自身对照的临床试验方法,采用索利那新5mg和坦索罗辛0.2mg,每日1次口服,对50例BPH伴OAB患者进行了为期4周的治疗。于治疗前后,以国际前列腺症状评分（IPSS）包括生活质量评估（QOL）及尿流率参数最大尿流率（Qmax）、平均尿流率（Qave）和尿量（VV）,以及排尿日记参数24时排尿次数、尿急次数、急迫性尿失禁次数和夜尿次数为评估指标,观察其有效性及安全性。结果服药4周后,可评价病例46例。IPSS总分及QOL单项评分显著改善,IPSS平均降低9.25分（P〈0.01）,其中排尿症状评分平均降低3.37分（P〈0.01）,储尿症状评分平均降5.88（P〈0.01）;QOL平均降低2.45分（P〈0.01）。治疗前后的尿流率参数值（Qmax、Qave、VV）有增加,差异均有统计学意义（P〈0.05）。治疗后排尿日记4项参数均显著减少（P〈0.01）。治疗过程中不良事件发生率4.35%（1例患者出现口干,1例出现头痛）,无1例出现尿潴留。结论索利那新联合坦索罗辛治疗对良性前列腺增生（BPH）引起的下尿路症状合并膀胱过度活动症（OAB）的患者有效安全。

Efficacy of Solifenacin and Tamsulosin for Treatment of Men with Lower Urinary Tract Symptoms and Overactive Bladder

Objective To assess the efficacy and safety of solifenacin and tamsulosin for the treatment of benign prostatic hyperplasia（BPH） patients with lower urinary tract symptoms（LUTS） and overactive bladder（OAB） . Methods Fifty BPH patients with OAB symptoms were treated with solifenacin 5 mg and tamsulosin 0.2 mg once daily for 4 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores（IPSS） ,quality of life indexes（QOL） ,maximum urinary flow rates（Qmax） ,average urinary flow rates（Qave） ,voiding volumes（VV） ,daily micturition frequency,daily frequency of urgency incontinence,urgency and nocturia obtained before and after the treatment. Results After 4 weeks medication,46 assessable cases showed an average decrease of 9.25 in IPSS（P 0.01） ,3.37 in voiding symptom score（P 0.01） ,5.58 in urinary storage symptom score（P 0.01） and 2.45 in QOL（P 0.01） ,and a significant increase in Qmax、Qave and VV. Only 4.35% patients experienced the adverse event. Conclusion Combining solifenacin and tamsulosin is both effective and safe in the treatment of BPH patients with LUTS and OAB.